MDY vs XBI
SPDR S&P MidCap 400 ETF Trust vs SPDR S&P Biotech ETF
- • MDY has the lower expense ratio at 0.23% vs 0.35% for XBI.
- • MDY pays a higher dividend yield (1.00%).
Side-by-side metrics
| Metric | MDY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.23% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.00% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $28.05B | $10.73B |
YTD return | 13.52% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.99 | 1.10 |
P/E ratio | 22.07 | — |
Last price | $690.22 | $164.28 |
Inception | — | — |
Issuer | State Street | State Street |
MDY top holdings
| FLEX | Flex Ltd | 1.58% |
| TWLO | Twilio Inc Class A | 0.82% |
| FTI | TechnipFMC PLC | 0.79% |
| CW | Curtiss-Wright Corp | 0.79% |
| NVT | nVent Electric PLC | 0.77% |
| STRL | Sterling Infrastructure Inc | 0.75% |
| XPO | XPO Inc | 0.72% |
| P | Everpure Inc Class A | 0.71% |
| ILMN | Illumina Inc | 0.71% |
| UTHR | United Therapeutics Corp | 0.68% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About MDY
MDY (SPDR S&P MidCap 400 ETF Trust) is Tracks the S&P MidCap 400 index. Managed by State Street, the fund carries $28.1B in assets under management, an expense ratio of 0.23%, a dividend yield of 1.00%. Its largest holding is Flex Ltd (FLEX), which represents 1.6% of the portfolio. Real Estate is the fund's largest sector exposure at 7.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.